$PGNY

Cummings Melissa B sold $71K of PGNY

Cummings Melissa B (Chief Operating Officer) sold 2,244 shares of Progyny, Inc. (PGNY) at $31.60 on 2026-07-14 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Cummings Melissa B
Published Jul 16, 2026, 8:16 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 16, 2026, 8:28 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$PGNY
Neutral
high confidence
Mentioned
$PGNY
Relevance
2/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PGNYNeutralLow
01

Why it matters

The disclosure provides transparency on insider activity but does not include new guidance, litigation, financing, or operational milestones.

02

Market read

Traders may note insider selling, but the 10b5-1 pre-arranged nature and modest dollar value limit trading impact.

03

What to watch

The sale size ($70.9K) is relatively small versus typical institutional flows, and the 10b5-1 structure suggests timing is pre-set rather than information-driven.

Relevance 2/10Novelty 3/10Timing: Filed 2026-07-16, disclosing a 2026-07-14 insider sale.

Background

The article is a SEC Form 4 insider transaction disclosure for Progyny, Inc.

Company-level read

Ticker impact

$PGNYNeutralHigh confidence
Context

Progyny COO Melissa B Cummings sold 2,244 shares on 2026-07-14 under a pre-arranged 10b5-1 plan, totaling about $70.9K.

Expected impact

Low likelihood of a sustained price move based solely on this Form 4 sale.

Evidence & confidence

The filing specifies an open-market sale code S and confirms a pre-arranged 10b5-1 plan, which typically reduces interpretive weight versus discretionary selling.

Market effects

Minimal, as the disclosure is company-specific and not tied to operational or regulatory developments.

None indicated.

None indicated.

Counterpoint

Even with a 10b5-1 plan, repeated insider selling can coincide with internal caution, so some traders may treat it as a mild negative sentiment input.

Key entities

  • Progyny, Inc.

    Company whose COO insider sale is disclosed via SEC Form 4.

  • Melissa B. Cummings

    Chief Operating Officer who sold 2,244 shares under a pre-arranged 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CVSMedAI 8/10

Health Insurance Providers Stocks Q2 Teardown: Clover Health (NASDAQ:CLOV) Vs The Rest

CVS Health (CVS) reported $106.1B revenue, up 7.3% YoY, beating estimates. Despite strong earnings, its stock fell 10.2% to $93.76. Progyny (PGNY) reported $350.5M revenue, up 5.3% YoY, but missed EBITDA guidance, causing a 15.3% stock drop to $25.58. Cencora (COR) reported $84.75B revenue, up 5.1% YoY, in line with expectations, with a 3.2% stock increase to $316.20. UnitedHealth (UNH) reported $112B revenue, flat YoY, beating estimates, but its stock fell 7.1% to $388.62.

$PGNYHigh

This fertility benefit business is set to boom. Buy the stock now, Wells Fargo says

Wells Fargo initiated coverage of Progyny with an overweight rating and $37 price target, implying 45% upside. The analyst cited demographic trends, corporate wellness focus, and healthcare innovation as drivers. Progyny's market share growth, global expansion, and new offerings were highlighted. Nine of 11 analysts rate the stock a buy or strong buy, with shares up 13% over the past year.

$PGNYMedAI 8/10

Progyny (PGNY) Q2 2026 Earnings Call Transcript

Progyny (PGNY) reported Q2 2026 revenue of $350.5 million, up 5.3% reported (11% excluding a transition agreement), and net income of $28.1 million ($0.34/diluted share). Adjusted EBITDA rose to $62.1 million, with gross margin expanding to 25.5%. Fertility benefit revenue was $230.2 million. Full-year 2026 guidance: revenue $1.36B to $1.385B, adjusted EBITDA $233M to $240M.

$PGNYMedAI 8/10

Progyny (PGNY) Q2 2026 Earnings Call Transcript

Progyny (PGNY) reported Q2 2026 revenue of $350.5M (+5.3% reported, +11% excluding a transition agreement), net income of $28.1M ($0.34/share), and adjusted EBITDA of $62.1M (17.7% margin). Fertility benefit revenue was $230.2M and pharmacy $120.3M. Guidance: 2026 revenue $1.36B-$1.385B and adjusted EBITDA $233M-$240M; Q3 revenue $335M-$345M.